Overview
The goal of this clinical trial is to compare the use of a specific drug eluting balloon (Magic Touch, Concept Medical®) versus standard drug eluting stent based strategies in patients with long coronary lesions.
Participants with chronic coronary disease and long coronary stenosis will be randomly assign to be treated either with Magic Touch balloon or drug eluting stent.
Description
Patients at coronary angiography who are deemed suitable for PCI are assessed for eligibility. Patients fulfilling all inclusion and no exclusion criteria can be consented for trial participation. After successful lesion preparation, defined as residual stenosis less than 30%, TIMI flow 3 and no major (type C) dissection of target lesion, consented patients will be randomized in a 1:1 ratio to a drug eluting balloon(DEB)-based or standard drug eluting stent(DES)-based strategy and further randomized in a 1:1 fashion, stratified based on DEB vs DES, to undergo invasive follow-up at 6 (±30 days) or 12 (±30 days) months.
Eligibility
Inclusion Criteria:
- Adult patients (≥18 years old) with chronic coronary syndrome deemed suitable for PCI
- At least one significant de-novo coronary lesion (defined as diameter stenosis \> 50% on angiography, with flow limiting features, confirmed with FFR ≤0.80 or iFR ≤0.89 and intended implantation of a long (≥30 mm) DES based on IVUS findings
- Written informed consent
Exclusion Criteria:
- Patients referred to the index procedure for an acute coronary syndrome
- Target lesion involving the left main and/or ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery
- Severe renal impairment (eGFR\<15ml/min/1.73m2) or patient on dialysis treatment
- Spontaneous coronary artery dissection (SCAD)
- Contraindications to adenosine administration (e.g. moderate to severe asthma or chronic obstructive pulmonary disease, heart rate \<50 beats/min and systolic blood pressure \<90 mmHg)
- Known pregnancy or breast-feeding patients
- Life expectancy \<1 year due to other severe non-cardiac disease
- Legally incompetent to provide informed consent
- Participation in another clinical study with an investigational product
